FDA Okays Amgen's Prolia, But With Hefty Post-Marketing Requirements In Tow
This article was originally published in The Pink Sheet Daily
Executive Summary
Denosumab will be indicated for use in postmenopausal women with osteoporosis who are at high risk for fractures.